

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB04/005080

International filing date: 06 December 2004 (06.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: GB
Number: 0328157.3
Filing date: 04 December 2003 (04.12.2003)

Date of receipt at the International Bureau: 24 January 2005 (24.01.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



GB 04/5080



INVESTOR IN PEOPLE

The Patent Office
 Concept House
 Cardiff Road
 Newport
 South Wales
 NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.


In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated

24 December 2004




Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office

Cardiff Road
Newport
South Wales
NP9 1RH



1. Your reference

P36085GB/PWC

2. Patent application number

(The Patent Office will fill in this part)

04 DEC 2003

0328157.3

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Imperial College Innovations Ltd
Imperial College
Exhibition Road, London SW7 2AZ

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom

740943600

4. Title of the invention

Compounds

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

Kilburn & Strode
20 Red Lion Street
London
WC1R 4PJ

Patents ADP number (if you know it)

125001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

a) any applicant named in part 3 is not an inventor, or

b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body.

See note (d))

NO

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 27

Claim(s) 6

Abstract 0

Drawing(s) 0 *RAM*

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

Date 04/12/2003

12. Name and daytime telephone number of person to contact in the United Kingdom

Paul Chapman
Tel: 020 7539 4200

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

COMPOUNDS

The present invention relates to novel compounds and their use in the inhibition of phosphatases, particularly inositol phosphatases. The compounds thus find use in treating neurodegenerative diseases as well as other conditions where inhibition of apoptosis would be beneficial.

Vanadate, peroxovanadium (pV) and bisperoxovanadium (bpV) derivatives are well known inhibitors of protein tyrosine phosphatases (PTPases) whereby bpVs are more potent than the other two molecule classes [Posner, 1994 #157] [Cuncic, 1999 #221].

Vanadate, a phosphate analogue, is a competitive inhibitor of PTP-1B while pervanadate irreversibly oxidizes the catalytic cysteine of PTP-1B [Huyer, 1997 #220]. Peroxovanadium compounds which show higher stability than pervanadates have been recently synthesised [Posner, 1994 #157]. Beside other biological functions they all exhibit insulin mimetic features [Rumora, 2001 #153], e. g. increase of glucose transport in adipocytes [Shisheva, 1993 #260], enhancement of insulin receptor-mediated tyrosine phosphorylation of insulin receptor substrate (IRS)-1 [Wilden, 1995 #259] and induction of insulin receptor kinase (IRK) phosphorylation by inhibiting IRK-associated PTPases [Band, 1997 #155].

The insulin mimetic downstream effect is thought to be mainly originated by the inhibition of PTPases that are involved in dephosphorylating the insulin receptor resulting in a prolonged insulin signal [Shechter, 1990 #258]. All PTPases share the same active site the so-called CX5R motif. This sequence homology has been also found in some phosphoinositol phosphatases such as the SAC phosphatase, Myotubularin (MTM) and PTEN (phosphatase and tensin homologue deleted on chromosome 10) (for review: see No 98). The latter was originally thought to be a PTPase but has subsequently been shown to possess higher affinity towards 3-phosphorylated phosphoinositides (PI) such as PI(3)P, PI(3,4,5)P3 and I(3,4,5)P4 [Maehama, 1998 #175].


PTEN is a tumour suppressor which in many cancer cells is either mutated or deleted [Li, 1997 #255] [Steck, 1997 #256] [Waite, 2002 #262] (No 289). 3-phosphorylated lipids are mainly generated by the phosphoinositol 3 kinase (PI3K) in response to an extracellular stimulation. By dephosphorylating intracellular PI(3,4,5)P3 PTEN

counteracts the PI3K and therefore inhibits the protein kinase B (PKB) activity (No 232, No 236, No 265) one of the main downstream targets of PI3K. PKB also referred to Akt [Downward, 1998 #254] is the mammalian homologue of the viral oncoprotein v-akt (No 284). Since PI(3,4,5)P3 is an important second messenger involved i. e. in cell growth signalling, [Stephens, 1993 #257] one can say that PTEN terminates important signalling pathways in the cell leading to apoptosis (No 202).


In addition, PTEN has been shown to block cell cycle progression by negative regulation of the PI3K/PKB pathway (No 235) and is involved in the regulation of angiogenesis (No 191). The loss of PTEN in malignant melanoma led to the activation of PKB (No 275). Stocker et al [Stocker, 2002 #186] have recently shown that in a Drosophila mutant lacking PTEN increased levels of PI(3,4,5)P3 directly effect PKB. PI(3,4,5)P3 binds to a N-terminal pleckstrin homology (PH) domain of PKB and subsequently leads to conformational changes (No 287) and its recruitment to the membrane. Upon translocation PKB is phosphorylated at two major sites (Thr308 and Ser473) which is crucial for its activity (No 285). Threonine is phosphorylated by the phosphoinositol dependent kinase-1 (PDK-1) (No 286) which in turn is activated by PI(3,4,5)P3 binding to their PH domains (for review see: [Downward, 1998 #254][Hill, 2002 #237]). The kinase which phosphorylates the serine residue remains unknown.

We have now found that certain Vanadium based compounds represent a new class of PTEN inhibitors, the bpV compounds. These inhibitors show significant lower IC₅₀ values for PTEN as demonstrated for PTPases, *in vitro* and *in vivo*. Thus, the use of these molecules allows the distinction between different groups of phosphatases.

Thus, in a first aspect, the present invention provides the use of a Vanadium containing compound of the formula:




wherein L-L' is :



5


and L' is COO, CONR⁵, CONHR⁶, CH₂NR⁵R⁶

or wherein L and L' together form a group:



10

or a group:



15

wherein L'' is O, S or NH;

R¹, R², R³, R⁴, R⁵ and R⁶ are independently H, C₁₋₆ alkyl, optionally substituted by hydroxy or NR⁷R⁸, C₃₋₆ cycloalkyl, optionally substituted by hydroxy or NR⁷R⁸, phenyl, optionally substituted by C₁₋₃ alkyl, hydroxy, NR⁷R⁸ or SO₃, (OCH₂CH₂)_n

(NHCH₂CH₂)_n, an amino acid or a peptide consisting of 2 to 5 amino acids; and


R⁷ and R⁸ are independently H or C₁₋₆ alkyl;

or a pharmaceutically acceptable salt thereof

in the manufacture of a medicament for use in inhibiting phosphatases.


In a second aspect the present invention provides a Vanadium containing compound of the formula:

5



wherein L-L' is :


10




and L' is COO, CONR⁵, CONHR⁶, CH₂NR⁵R⁶

or wherein L and L' together form a group:

15



or a group:



wherein L' is O, S or NH;

R¹, R², R³, R⁴, R⁵ and R⁶ are independently H, C₁₋₆ alkyl, optionally substituted by hydroxy or NR⁷R⁸, C₃₋₆ cycloalkyl, optionally substituted by hydroxy or NR⁷R⁸, phenyl, optionally substituted by C₁₋₃ alkyl, hydroxy, NR⁷R⁸ or SO₃, (OCH₂CH₂)_n (NHCH₂CH₂)_n, an amino acid or a peptide consisting of 2 to 5 amino acids; and R⁷ and R⁸ are independently H or C₁₋₆ alkyl; or a pharmaceutically acceptable salt thereof

in the manufacture of a medicament for use in inhibiting phosphatases.

Preferred compounds for use in the invention include potassium bisperoxo (bipyridine) oxovanadate (bpV(bipy)), potassium bisperoxo(1,10-phenanthroline)oxovanadate (pV(phenanthroline)), potassium bisperoxo (piconilinate) oxovanadate (pV(pic)) and potassium bisperoxo(phenylbiguanide)oxovanadate (pV(biguan)).

The peroxovanadates derived from the R¹R²N-C(=NH)-NH-C(=E)-NR³R⁴, (E = NH, S, O) ligands are novel compounds and represent independent aspects of the invention. Similarly, the peroxovanadates derived from the 2-piconilamide ligands (whether they are N,N or N,O coordinated) are also novel representing independent aspects of the invention.

As discussed herein, the compounds described herein find use as inhibitors of phosphatases, in particular PTEN. As such, therefore, they find use as treatments of neurodegenerative disease such as Alzheimer's disease as well as diseases or conditions which benefit from inhibition of apoptosis, such as wound healing, burns, heart hypertrophy, hypoxia, ischemia and sports injuries. In addition, cancer cells are more resistant to apoptosis and thus the compounds of the invention would find use in combination with conventional chemotherapy agents as protecting normal cells, which are more likely to undergo apoptosis.

The medicaments as described herein may be presented in unit dose forms containing a predetermined amount of each active ingredient per dose. Such a unit may be adapted to provide 5-100mg/day of the compound, preferably either 5-15mg/day, 10-30mg/day, 25-50mg/day 40-80mg/day or 60-100mg/day. For compounds of formula I, doses in the range 100-1000mg/day are provided, preferably either 100-400mg/day, 300-600mg/day or 500-1000mg/day. Such doses can be provided in a single dose or as a number of discrete doses. The ultimate dose will of course depend on the condition being treated, the route of administration and the age, weight and condition of the patient and will be at the doctor's discretion.

The compounds described herein are most preferably administered in the form of appropriate compositions. As appropriate compositions there may be cited all compositions usually employed for systemically or locally administering drugs. The pharmaceutically acceptable carrier should be substantially inert, so as not to act with the active component. Suitable inert carriers include water, alcohol, polyethylene glycol, mineral oil or petroleum gel, propylene glycol and the like. Said pharmaceutical preparations may be formulated for administration in any convenient way for use in human or veterinary medicine.

As described in detail below, the pharmaceutical compositions of the present invention may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration, for example, by subcutaneous, intramuscular or intravenous injection as, for example, a sterile solution or suspension; (3) topical application, for example, as a cream, ointment or spray applied to the skin; or (4) intravaginally or intrarectally, for example, as a pessary, cream or foam. However, in certain embodiments the subject agents may be simply dissolved or suspended in sterile water. In certain embodiments, the pharmaceutical preparation is non-pyrogenic, i.e., does not elevate the body temperature of a patient. The phrase "effective amount" as used herein means that amount of one or more agent, material, or composition comprising one or more agents of the present invention which is effective for producing some desired effect in an

animal. It is recognized that when an agent is being used to achieve a therapeutic effect, the actual dose which comprises the "effective amount" will vary depending on a number of conditions including the particular condition being treated, the severity of the disease, the size and health of the patient, the route of administration, etc. A skilled medical practitioner can readily determine the appropriate dose using methods well known in the medical arts. The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

The phrase "pharmaceutically acceptable carrier" as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject agents from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation. Some examples of materials which can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations.

In certain embodiments, one or more agents may contain a basic functional group, such as amino or alkylamino, and are, thus, capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable acids.

The term "pharmaceutically acceptable salts" in this respect, refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or by separately reacting a purified compound of the invention in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like (Berge, Bighley et al. 1977). The pharmaceutically acceptable salts of the agents include the conventional nontoxic salts or quaternary ammonium salts of the compounds, e.g., from non-toxic organic or inorganic acids. For example, such conventional nontoxic salts include those derived from inorganic acids such as hydrochloride, hydrobromic, sulfuric, sulfamic, phosphoric, nitric, and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, palmitic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isothionic, and the like. In other cases, the one or more agents may contain one or more acidic functional groups and, thus, are capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable bases. These salts can likewise be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form with a suitable base, such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary or tertiary amine.

Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts and the like. Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like. (see, for example, Berge et al., supra) Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and

antioxidants can also be present in the compositions. Examples of pharmaceutically acceptable antioxidants include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.

Formulations of the present invention include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and/or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration.

The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred per cent, this amount will range from about 1 percent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent. Methods of preparing these formulations or compositions include the step of bringing into association an agent with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association an agent of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.

Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient. A compound of the present invention may also be administered as a bolus, electuary or paste. In solid dosage forms of the invention for oral administration (capsules,

tablets, pills, dragees, powders, granules and the like), the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like. A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.

The tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately

before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients. Liquid dosage forms for oral administration of the compounds of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents. Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.

Formulations of the pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the agents. Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.

Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions

with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required.

The ointments, pastes, creams and gels may contain, in addition to an active
5 compound of this invention, excipients, such as animal and vegetable fats, oils, waxes; paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof. Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or
10 mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane. Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body. Such dosage forms can be made by dissolving or dispersing the agents in the proper medium.
15 Absorption enhancers can also be used to increase the flux of the agents across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel.

Ophthalmic formulations, eye ointments, powders, solutions and the like, are also
20 contemplated as being within the scope of this invention. Pharmaceutical compositions of this invention suitable for parenteral administration comprise one or more compounds of the invention in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable
25 solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents. Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such
30 as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin. In some cases, in order to prolong the effect of an agent, it is desirable to slow the absorption of the agent from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the agent then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered agent form is accomplished by dissolving or suspending the agent in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of agent to polymer, and the nature of the particular polymer employed, the rate of agent release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the agent in liposomes or microemulsions which are compatible with body tissue.

When the compounds of the present invention are administered as pharmaceuticals, to humans and animals, they can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of active ingredient in combination with a pharmaceutically acceptable carrier. Apart from the above-described compositions, use may be made of covers, e.g., plasters, bandages, dressings, gauze pads and the like, containing an appropriate amount of a therapeutic. As described in detail above, therapeutic compositions may be administered/delivered on stents, devices, prosthetics, and implants.

Compounds as described herein can be synthesised according to the following general procedures:

Synthesis of peroxovanadates with general formula: $[M]_n[V(=O)(O_2)_2(L-L)]$

5 (where M = Na, K or NH_4)

In a typical procedure $K_2[V(=O)(O_2)_2(pic)] \cdot H_2O$ (pic = pyridine-2-carboxylate) was prepared by adding distilled water to V_2O_5 (0.69 g, 3.8 mmol) and KOH (0.49 g, 8.8 mmol) to form a yellow-brown suspension. This was followed by addition of H_2O_2 10 (0.5 ml of a 30% w/v) which produced a bright orange solution with some brown precipitate. The brightly colored solution was filtered through a sinter glass filter and allowed to stand for 30 minutes. More H_2O_2 (10 ml) was added to the reaction mixture followed by addition of picolinic acid (0.97 g, 7.9 mmol). The solution was stirred for further 30 minutes after which time ethanol (40 ml) was added dropwise 15 precipitating a bright yellow compound. This solution was left standing at 4°C for two days and all yellow solid produced was collected by filtration, washed 3 times with dry ethanol and dried under reduced pressure overnight (yields vary between 40 and 80% depending on the L-L ligand used). The pV complexes can be characterized by infrared, uv visible, 1H NMR and ^{51}V NMR spectroscopy. Elemental analyses can be 20 used to confirm the purity of the samples.

This synthetic procedure is based in previously reported ones:

[1] Alan Shaver, Jesse B. Ng., David A. Hall, Bernadette Soo Lum, and Barry I. 25 Posner, *Inorg. Chem.* **1993**, 32, 3109-3113

[2] Barry I. Posner, Robert Faureb, James W. Burgess, A. Paul Bevand, Danielle Lachance, Guiyi Zhang-Sun, I. George Fantus, Jesse B. Ng, David A. Hall, Bernadette Soo Lum and Alan Shavers, *J. Biol. Chem.* **1994**, 269, 4596-4604

Synthesis of vanadates with general formula: $[V(=O)(L-L)_2]$ and $[M]_2[V(=O)(L-L)_2]$ ($M = Na, K, NH_4$)

In a typical procedure $[V(=O)(pic)_2] \cdot H_2O$ was prepared by adding a solution of
5 picolinic acid (0.83 g, 6.5 mmol) in water (20 mL) to $[V(=O)(SO_4)] \cdot 3H_2O$ (0.72 g, 3.30 mmol) in water (20 mL). The pH was raised to 4.4 with dropwise additions of 2 M NaOH. The light blue solid which precipitated was isolated by filtration and washed with methanol and diethyl ether several times. The solid was dried under reduced pressure (yields vary between 45 and 90% depending on the L-L ligand
10 used). The vanadate complexes can be characterized by infrared and uv visible spectroscopy, mass spectrometry and magnetic momentum determination. Elemental analyses can be used to confirm the purity of the samples.

This synthetic procedure is based in previously reported ones:

15

[1] Marco Melchior, Katherine H. Thompson, Janet M. Jong, Steven J. Rettig, Ed Shuter,

Violet G. Yuen, Ying Zhou, John H. McNeill, and Chris Orvig, *Inorg. Chem.* **1999**, 38, 2288-2293

20

In a third aspect, the present invention provides a method of inhibiting a phosphatase which comprises administering to a subject an effective amount of a compound as described herein. In particular, the phosphatase is PTEN and more particularly, the invention provides a method of treating a neurodegenerative disease such as
25 Alzheimer's disease as well as diseases or conditions which benefit from inhibition of apoptosis, such as wound healing, burns, heart hypertrophy, hypoxia, ischemia and sports injuries. In addition, cancer cells are more resistant to apoptosis and thus the compounds of the invention would find use in combination with conventional chemotherapy agents as protecting normal cells, whci are more likely to undergo
30 apoptosis.

The invention will now be described with reference to the following examples, which should not in any way be construed as limiting the invention:

EXAMPLE 1

Cloning and Expression of PTEN

- 5 The coding region of the DNA sequence of human PTEN was cloned into a pGEX-4T2 expression vector (Pharmacia). Protein expression was induced overnight in the *Escherichia coli* DH5 α strain using 100 μ M IPTG at 18 C. GST-fusion proteins were purified according to the manufacturer's manual using glutathione sepharose 4B (Pharmacia). Protein integrity and specificity were confirmed on a Western Blot using
- 10 GST antibody (Novagen).

Synthesis of bpV(pic)

- $K_2[V(=O)(O_2)_2(pic)] \cdot H_2O$ (pic = pyridine-2-carboxylate) was prepared by adding distilled water to V_2O_5 (0.69 g, 3.8 mmol) and KOH (0.49 g, 8.8 mmol) to form
- 15 a yellow-brown suspension. This was followed by addition of H_2O_2 (0.5 ml of a 30% w/v) which produced a bright orange solution with some brown precipitate. The brightly colored solution was filtered through a sinter glass filter and allowed to stand for 30 minutes. More H_2O_2 (10 ml) was added to the reaction mixture followed by addition of picolinic acid (0.97 g, 7.9 mmol). The solution
- 20 was stirred for further 30 minutes after which time ethanol (40 ml) was added dropwise precipitating a bright yellow compound. This solution was left standing at 4°C for two days and all yellow solid produced was collected by filtration, washed 3 times with dry ethanol and dried under reduced pressure overnight (yields vary between 40 and 80% depending on the L-L ligand used).
- 25 Yield: 1.62 g, 58. %. This compound was characterised by NMR and IR spectroscopy and its purity established by elemental analysis. Elemental analyses: Found: C, 19.7; H, 2.0; N, 3.7. Calculated for $C_6H_4NO_7K_2V \cdot 2H_2O$: C,

19.6: H, 2:1; N, 3:8; IR v (KBr): 1630 (C=O), 951 (VO), 860, 872 (OO) cm^{-1} ; ^1H NMR (D₂O): 7.44.1 ppm.

5 Protein tyrosine phosphatase (PTPase) assay

Protein tyrosine phosphatase (PTPase) assays were performed using the synthetic substrate p-nitrophenylphosphate (pNPP) and the phosphatases PTP-1B and PTP- \square (Upstate Biotechnology). The standard assay conditions were 25 mM HEPES pH 7.2, 50 mM NaCl, 5 mM DTT, 2.5 mM EDTA, 100 $\mu\text{g}/\text{ml}$ BSA, 1 mM pNPP (Sigma) and
10 4 unit PTP-1B and 10 unit PTP- \square , respectively. The assay was started by adding the enzyme and was carried out for 15 min at 30 C in a preheated ELISA reader chamber. The linear increase of absorbance was monitored every 30 seconds at a wavelength of 410 nm. Inhibition studies were performed in the same assay system containing PTPase inhibitors such as bpV(bipy), bpV(HOpic), and bpV(phen) (Calbiochem) and
15 the synthesised compound bpV(pic) at concentrations between 100 μM and 1 nM.

Malachite green phosphate release assay and IC_{50} studies with PTEN

Enzyme activity of recombinant PTEN was measured with a malachite green dye based phosphate release assay (No 230, No 83). The standard assay conditions were
20 200 mM Tris pH 7.4, 50 ng/ μl BSA, and 15 ng/ μl PTEN. The synthetic lipid PI(3,4,5)P3dC16 (Cell Signals) was used as a substrate for PTEN. The lipid was dissolved in methanol/ H_2O and stored at -20°C . Prior to the use in these PIPase experiments, an appropriate amount of lipid was dried down and resuspended in 1% Octylglycoside (Sigma). After 10 min of sonication lipid samples were ready to be
25 added to the enzyme assay. All assays were started by adding the enzyme into the preheated buffer solution, containing PI(3,4,5)P3dC16. Linear PIPase reactions were performed at 30 C for 30 min in an incubation chamber. In order to stop the enzyme reaction, 0.7 volume of colour reagent (2.3 mg/ml malachite green in 3.6 M HCl and 17 mM ammonium molybdate) was added to the enzyme solution. The mixture was
30 allowed to develop for 20 min and the absorbance at 625 nm was measured. For all inhibitor studies inhibitor concentrations from 0.1 nM up to 500 nM were pre-incubated with PTEN and the enzyme assays were started by adding 150 μM

sonicated lipid. To normalize the phosphate release a phosphate standard curve was used. All experiments were repeated in triplets. Calculations for IC₅₀ values were performed using GraphPad Prism.

5 Cytotoxicity assay

Cytotoxicity of bpV compounds was measured doing MTT assays. NIH3T3 cells were resuspended in serum-free media and exposed to concentrations of all four bpV compounds between 1 mM and 0.1 nM for 2 h. MTT solution (5 mg/ml) (Lancaster Synthesis Ltd) was added to the cells and further incubated for 4 h. Cell pellets were
10 resuspended in DMSO containing 100 mM HCl and measured at 570 nm.

Phalloidin staining

In order to monitor morphological changes NIH3T3 cells were grown on 8-well chamber slides and incubated with concentrations of bpV(pic) and bpV(phen)
15 between 0.1 and 10 μ M for 6 h and 24 h, respectively. Fibroblasts were fixed with 4% para-formaldehyde (PFA), permeabilised with 0.2% Triton and blocked with 10% NCS (newborn calf serum). To stain actin filaments cells were incubated with TRITC-phalloidin (Sigma) (1:1000) for 1 h. Finally, nuclei were DAPI (Sigma) stained and mounted. Morphological analyses were assessed on a ... microscope using filters for
20 TRITC and DAPI and pictures were captured using a ... camera.

Tissue culture

NIH3T3 cells (passage 5-20) were grown in 10% NCS D-MEM (GIBCO BRL) in 6-well plates at 37 C and 5% CO₂. Starvation of the cells was carried out over 72 h in
25 D-MEM containing 0.5% NCS. Prior use medium was changed to 0% D-MEM. UM-UC-3 cells which is a PTEN⁻ bladder tumour cell line (N0 195, No 196) were grown in 10% MEM (GIBCO BRL), starved with 0.5% MEM also for three days and finally incubated with serum free MEM.

30 PKB assay: activation of the insulin signalling pathway by bpV compounds

In order to establish the insulin mimetic property of the four bpV compounds NIH3T3 and UM-UC-3 cells were exposed to bpV(bipy), bpV(phen), bpV(HOpic) and

bpV(pic) with concentrations of 0.1, 1 and 10 μ M for 15 min. Cells were washed once with PBS and lysed using 80 μ l SDS-PAGE buffer (250 mM Tris pH 6.8, 20% glycerol, 4% SDS, 0.01% bromophenol blue, 50 mM mercaptoethanol). Samples were boiled for 15 min and stored at -20 C until analysis on Western Blots as described in the last paragraph.

Phosphotyrosine assay with NIH3T3 cells

NIH3T3 cells were grown and starved as described earlier. After 72 h starvation cells were incubated for 15 min with 10% NCS, 50, 10 and 0.5 μ g/ml insulin (Sigma), 10, 1, 0.1 and 0.01 μ M bpV(pic) and bpV(phen), respectively. Cell lysates were prepared as described above and all samples were analysed on Western Blots using an anti phospho-tyrosine antibody (Upstate).

PKB assay in the presence of PI3K inhibitor Ly294002 and mTOR inhibitor rapamycin

In order to study the influence of PI3K and mTOR on the bpV-dependent insulin mimetic feature we treated NIH3T3 cells with 10 μ M LY294002 (Promega) and 50 nM rapamycin (Calbiochem) for 20 min and 30 min, respectively, followed by an incubation with 10 μ M or 1 μ M bpV(pic) for 15 min. Cell lysates were analysed on PKB Western Blots.

PKB assay: dose dependence of the inhibitory effect of bpV compounds on PTEN

For studying the inhibitory potency of the vanadate molecules on PTEN bpV(bipy), bpV(HOpic), bpV(pic) and bpV(phen) were added to the cells with concentrations from 1 nM up to 100 nM for 5 min, followed by a stimulation with 0.5 μ g/ml insulin for 15 min. UM-UC-3 cells were treated in exactly the same manner. Cell samples were analysed on Western Blots with PKB antibodies.

Ly294002 dose dependence

In order to find out whether bpV(pic) has an influence on Ly294002-dependent PKB inhibition we accomplished a dose response experiment applying concentrations from 0.01 up to 100 μ M Ly294002 to two sets of quiescent fibroblasts and incubated for 20 min. One batch of cells were then further treated with 200 nM bpV(pic) (5 min) and

all cells were finally stimulated with 10 μ g/ml insulin for 15 min. Cell lysates were collected as described earlier. Calculations and graph were performed using GraphPad Prism.

5

Western Blot analysis

All cell lysate samples were loaded on 10% SDS-PAGE and transferred to PVDF membranes for PKB analysis and nitrocellulose for phospho tyrosine detection. For PKB Western Blots membranes were blocked for 1 h with 5% milk powder in TBST followed by an incubation with anti Mass PKB antibody (1:1000) or anti phospho-PKB (Ser473) antibody (1:1000) in TBST for 2 h. Finally, membranes were exposed to a horseradish peroxidase-conjugated secondary antiserum (BIORAD) (1:1000) in 5% milk powder solution for 1 h. The Western Blots were developed with ECLTM solution (Amersham). In order to detect phosphorylated tyrosine residues nitrocellulose membranes were blocked for 1 h with 2.5% milk powder, first incubated with a specific-anti phosphotyrosine antibody (4G10) (1:3000) for 1 h, and finally with horseradish peroxidase-conjugated secondary anti mouse antiserum. All PKB and Phospho-Tyrosine experiments were accomplished in three independent experiments and all membranes were re-probed using a specific tubulin antibody (1:1000). Density analysis of bands took place using the public domain NIH Image V1.62 program (developed at the U.S. National Institutes of Health and available on the Internet at <http://rsb.info.nih.gov/ni-image/>). Intensity of the pS473 bands were standardised with those of the corresponding Mass PKB and expressed as an arbitrary unit in order to demonstrate changes to controls.

25

RESULTS

IC₅₀ for the protein tyrosine phosphatases PTP-1B and PTP- σ

PTPase assays were employed using pNPP as a substrate without and in the presence of bpV inhibitors. We demonstrated IC₅₀ values for each different compound (Table 1). One can distinguish two groups of bpV compounds, the aromatic (bpV(bipy) and bpV(phen)) and the polar inhibitors (bpV(HOpic) and bpV(pic)). PTP- σ assays with the aromatic molecules resulted in IC₅₀ values of 60.3 nM (+/-9.6) and 343 nM (+/-

88.5); respectively. These results correspond with values published earlier (No...).

Surprisingly, the IC_{50} for the two polar compounds bpV(HOpic) and bpV(pic) are as high as $4.9 \mu M$ (± 0.9) and $12.7 \mu M$ (± 3.2). Comparable results could be measured for the non-receptor like PTP-1B (for IC_{50} values see Table 1). The detected differences between the IC_{50} of these two groups of vanadates might be due to structural differences of their ligands. a bit more about structure and binding of inhibitors...

PTEN is inhibited by bpV compounds

IC_{50} analysis-PTEN is a 3-phosphatase that shows substrate affinity towards PI(3)P, PI(3,4,5)P3 and IP4. We established a phosphate release assay for the PTEN using PI(3,4,5)P3 as a substrate. This enzyme assay is based on a method which was established many years ago (No 230, No 83). Free inorganic phosphate was detected using an acidic malachite green dye (OD_{625}). This assay was established for the phosphoinositol phosphatase PTEN earlier (No 131). The K_m value for PTEN is about $150 \mu M$ which corresponds to a mol percentage of 1.72 (data not shown). Furthermore, we could establish for the first time that bpV compounds not only inhibit PTPs but also block phosphoinositol phosphatase activity of PTEN (SAC domain???). To further characterise the inhibitory potencies we accomplished IC_{50} studies by incubating an appropriate amount of PTEN with $150 \mu M$ PI(3,4,5)P3dC16 and various concentrations of all four bpV compounds. The results of the IC_{50} studies are summarised in Table 1. We measured surprisingly low IC_{50} s for all four inhibitors resulting in values between 14 and 38 nM. These numbers are 10 to 100fold lower than those for the PTPases indicating that this class of inhibitors shows much higher affinity to the active site of PTEN. Furthermore, we could not detect a significant difference between the two different groups of bpVs showing that binding of these vanadates in the active centre of PTEN is not affected by the different ligands. These findings characterise a new class of very potent PTEN inhibitors that can be exploited as highly useful tools in pharmacological studies in the future.

PKB assays: activation of the insulin signalling pathway by bpV compounds

It has been shown in the past that high doses of vanadate, pV and bpV resulted in PKB phosphorylation (No 184, 234). To assess this function of bisperoxo vanadates on the activation of the insulin signalling pathway we incubated starved NIH3T3 and

UM-UC-3 cells with concentrations ranging from 0.1 μ M up to 10 μ M of bpV(pic), bpV(HOpic), bpV(bipy) and bpV(phen). Fig 1a demonstrates the results revealed on PKB Western Blots using anti pS473 and Mass PKB antibodies. A concentration of 10 μ M gave the highest signal for phosphorylated PKB for all compounds in NIH3T3 cells. By using 1 μ M we still could detect a weak signal for bpV(pic), bpV(HOpic) and bpV(bipy), however, no phosphorylation was visible for bpV(phen). The lowest concentration (100 nM) did not result in phosphorylation of PKB for any of the pV compounds implying that the insulin mimetic property is detectable only in a μ molar range. Interestingly, bpV(phen) seemed to have lower potency to mimic the insulin pathways than the other molecules. This could be due to different targets in the signalling cascade. No further activation of phosphorylated PKB could be observed after a prolonged incubation time with the bpV molecules (data not shown). In comparison, results revealed in UM-UC-3 cells showed a higher background level of phosphorylated PKB due to the absence of PTEN in this cell line. Apart from that, stimulation of PKB occurred in a similar fashion as described for NIH3T3 cells. Assessment of the stability of all four inhibitors was performed by pre-incubation of the bpVs for up to 24 h. No differences could be observed (optical density was measured using NIH image) indicating that these molecules are highly stable in our assay conditions (data not shown). The Western Blot analysis for the mass PKB antibody showed consistent signals for all samples indicating a uniform expression level in all cells.

The bpV inhibitors increased phosphorylation of tyrosine residues. In order to detect the phosphorylation of tyrosine residues which is one main feature in insulin signalling pathways we incubated quiescent fibroblasts with different concentrations of bpV(pic) and bpV(phen) (10 μ M to 0.01 μ M), NCS (10%) and insulin (50, 10 and 0.5 μ g/ml). The Western Blot analysis for phosphorylated tyrosine residues revealed the typical pattern of protein bands (Fig 1b) of stimulated cells (No 277,278,279). The negative control showed a similar pattern however much weaker signals and some bands are absent. The highest degree of tyrosine phosphorylation could be detected in cells treated with 10 μ M bpV(pic) which is in correspondence to published data where phosphorylation of tyrosine residues was revealed with 10 μ M sodium orthovanadate (No 279), 100 μ M vanadate (No 282) or 0.5 mM pervanadate (No 238). These results showed that the highest dose of bpV(pic) is even more potent

than 50 $\mu\text{g/ml}$ insulin and 10% NCS. In correspondence to the results demonstrated in the PKB analysis 10 μM bpV(phen) effected lower stimulation than the equivalent concentration of bpV(pic). This gives another evidence that bpV(phen) has a lower insulin mimetic potency than the other compounds. Treatment with 1 and 0.1 μM bpV(pic) resulted in similar signals as revealed after incubation with 0.5 $\mu\text{g/ml}$ insulin. Furthermore, the lowest concentration (0.01 μM) is not distinguishable to the negative control. To summarise these results one can say that bpV compounds show insulin mimetic characteristics only in μmolar concentrations and that there is a remarkable diversity between the aromatic bpV(phen) and the polar bpV(pic) in means of tyrosine phosphorylation.

Cytotoxicity of bpV compounds

Doing MTT assays, a means of measuring the activity of living cells via mitochondrial dehydrogenases, we clearly showed that concentrations up to 10 μM of all four compounds had no effect on the survival of the fibroblasts (Fig 1c). Only a concentration as high as 100 μM is significantly cytotoxic killing about 40% of the cells. Treatment with 1 mM of the inhibitors led to the death of about 80% of the cells. This indicated that doses which can inhibit PTEN phosphatase activity *in vitro* do not affect cell viability. No difference in cytotoxicity could be observed between the four compounds.

Morphological changes after inhibitor exposure represented by actin re-arrangement NIH3T3 cells immuno stained with Phalloidin-TRITC and DAPI showed the cytoskeletal morphology of the fibroblasts. Actin staining of fibroblasts is a well-established techniques (No 280, No 281). The occurrence and distribution of actin stress fibers can be a mass of integrity of cells (No 283, No 266, No 271) and in turn cytotoxicity of drugs can be measured as a mean of actin arrangement. Control cells treated only with the vehicle displayed the classic cytoskeleton actin structure and the occurrence of stress fibers (Fig 2a-d). After treatment with 0.1 μM of bpV(pic) and bpV(phen) for 6 h and 24 h cellular morphology remained unchanged (Fig 2e-h). Only incubation with concentrations as high as 1 and 10 μM over 24 h revealed altered morphology characterised by the loss of actin stress fibers and the presence of thick areas of F-actin at the edges of affected cells (Fig 2k,j,l,n+p). Fibroblasts started to detach and die. Furthermore, cells and nucleus rounded up which are typical

features of dying cells (No...). Fibroblasts exposed to 1 and 10 μ M bpVs only for 6 h showed similar actin distribution and morphology as it could be seen in the control cells. These findings indicate that toxicity of the compound starts at μ molar concentrations. Furthermore, no significant differences could be observed within the two groups of bpV compounds giving evidence that in terms of cytotoxicity there exist no diversity between polar and aromatic bpV vanadates.

Influence of Ly294002 and rapamycin on bp vanadate induced insulin pathway
Ly294002 is a well-known PI 3-K inhibitor that blocks phosphorylation of PKB. In contrast, rapamycin inhibits mTOR, the so-called mammalian target of rapamycin. We investigated the influence of these two inhibitors on the bp vanadate induced insulin pathway. NIH3T3 cells were pre-incubated to an appropriate dose of Ly294002 and rapamycin and then exposed to 10 and 1 μ M bpV(pic), respectively. As demonstrated earlier starved, non-stimulated fibroblasts need μ molar concentrations of bpVs to induce phosphorylation of Ser473 of PKB (Fig 1a). As shown in Fig 3, 10 μ M bpV(pic) resulted in a high degree of phosphorylation. Addition of 50 nM rapamycin gave a similar stimulation, however pre-incubation with Ly294002 effected reduced phosphorylation rate. This proves that the phosphorylation of PKB by the vanadates is a PI 3-K dependent pathway. Additionally, we could show that at a concentration of 1 μ M bpV(pic) (longer exposure time Fig 3) no signal was visible, nevertheless pre-incubation with rapamycin provoked phosphorylated Ser473 implicating a role for mTOR in this signalling pathway.

bpV compounds stimulated PKB phosphorylation at nanomolar concentrations
Investigating the potency of bpV inhibitors we performed concentration dependent experiments with all four compounds. Quiescent NIH3T3 cells were incubated with concentrations of 1 nM up to 100 nM of bpV(HOpic), bpV(pic), bpV(bipy) and bpV(phen). The compounds induced the phosphorylation of PKB in a dose-dependent manner (Fig 4a). No activation could be established with the lowest concentrations such as 1 and 10 nM, however, a slight increase could be detected with 20 nM bpV(pic), bpV(HOpic) and bpV(bipy) (about 20%) in comparison with the control (0.5 μ g/ml insulin). Higher concentrations such as 60 nM to 100 nM resulted in a significant enhancement of the phosphorylated PKB signal. Optical density was measured using NIH Image program and IC₅₀ values could be calculated in relation to

the results of three independent experiment. These inhibition coefficients could be established between 48 nM (+/- 8.5) for bpV(pic) and 96 nM (+/- 16.3) for bpV(HOpic). To summarise these results, one can say that PTEN can also be inhibited with lower nanomolar concentrations of bpV compounds in vivo, as established in vitro (Table 1). Thus, the stimulation of PKB is due to increased *intracellular* PI(3,4,5)P3 levels provoked by PTEN inhibition. Furthermore, we could not detect any diversity between the two groups of inhibitors indicating that the active site of the PTEN phosphatase does not limit access in terms of size or charge. By establishing this distinct difference of inhibition in respect of PTPs and PTEN these molecules can be explored as useful tools to distinguish between various classes of phosphatases.

bpVs showed no effect on PKB phosphorylation in UM-UC-3 cells

To further prove the fact that bpVs inhibit PTEN and thus effect higher PI(3,4,5)P3 levels which leads to PKB phosphorylation we repeated the same experiments in the PTEN negative tumour cell line UM-UC-3. Starved UM-UC-3 cells were exposed to similar concentrations of all four inhibitors. The analysis of pS473 Western Blots did not show any stimulation of PKB (Fig 4b). Even the highest dose of 100 nM bpV inhibitors only increased the phosphorylation slightly implying that there occurred a shift of IC₅₀ for the bpVs. These results indicated once more that PTEN and subsequently PI(3,4,5)P3 are the key molecules in the activation of PKB induced by bpV compounds in our cell system.

PTEN inhibitor bpV(pic) can partly abrogate Ly294002 induced PKB inhibition

Quiescent NIH3T3 cells that were pre-incubated with various concentrations of Ly294002 (0.01 to 100 μ M) alone gave significantly lower signals on pSer473 Western Blots than those which were co-treated with 200 nM bpV(pic) (Insert Fig 5). This shift in IC₅₀ clearly demonstrated that bpV(pic) can abrogate Ly294002 induced PKB inhibition. The analysis of the optical density of the Western Blot signals were standardised to the control and calculated to means of inhibition. The graph shown in Fig 5 demonstrated significant differences for the experiments with and without bpV(pic). The presence of the bpV compounds effects a reduction of Ly294002 induced inhibition. These results give clear evidence that in our cell system bpVs act as PTEN inhibitors and subsequently increased PI(3,4,5)P3 levels resulted in phosphorylation of PKB.

DISCUSSION


For many years, PTEN has been described as a tumour suppressor being mutated in many cancer tissues (No 240, 246, 247, 267). It is now established that its role as a tumour suppressor is mainly exerted by the negative regulation of the PI3K/PKB signalling pathways (No, 236, 232, 265). Even though many recent studies are characterising PTEN as a phosphatase (see review No 98) and its role in metabolism and disease (No 267, 268, 246, 247) there exist no specific inhibitors for this protein. Studies are mainly accomplished in PTEN null cell lines (No 106, 164, 233, 236) or in a PTEN negative *Drosophila* mutant (No 175). The work presented here is the first study describing a very potent class of PTEN inhibitors. We could demonstrate that the well-known protein tyrosine phosphatase (PTPase) inhibitor class of bisperoxovanadiums (bpVs) show very high affinity towards PTEN. We characterised these compounds *in vitro* and *in vivo* and detected remarkable differences compared to the PTPase inhibitory properties. These insulin mimetics initiate pathways which are activated after growth factor stimulation of cells (No). Their features are mainly exhibited by inhibiting PTPases which dephosphorylates target protein such as insulin receptor substrate IRS-1 (No). In order to assess these insulin mimetic features of bpVs in our cell system we applied μ molar doses to fibroblasts and analysed phosphorylation degree of the Ser473 residue of PKB (Figure 1a) and tyrosine residues (Figure 1b). In correspondence to the literature (No 140, ...) we demonstrated increased level of phosphorylation in both cases.

In PTPase assays we revealed a clear difference between the polar (bpV(HOpic) and bpV(pic)) and the aromatic (bpV(phen) and bpV(bipy)) bpVs. The latter resulted in higher nanomolar IC_{50} values, however the polar compounds effected 50% inhibition at concentrations as high as μ molar (Table 1). Variations to published data (No...) might be due to assay conditions. It has been described that IC_{50} values may depend on buffer conditions such as DTT and EDTA concentration (No 146, 206). To analyse PTEN activity we performed phosphate release assays using an acidic malachite green dye (No 230, No 83). This assay has been successfully applied for PTEN (No 131) and gives linear results between 1 and 10 nmol of free inorganic phosphate (No 231). In the same study it was shown that this method is appropriate to investigate phosphatase activity in the presence of various inhibitors. Remarkably, inhibitory



studies applying all bpVs revealed PTEN inhibition already at low nanomolar concentration. This proves higher affinity of the bpVs towards PTEN. Furthermore, there was no significant difference detectable between the polar and the aromatic compounds as observed for the PTPases. This might be due to the more open structure of the active site of PTEN (No 165), whereby in clear contrast to that PTPases contain a closer structure (No Sonnenberg et al, 2003, Liu et al, 2003...). Based on these *in vitro* data, we performed *in vivo* studies using quiescent fibroblast that were treated with different concentrations of bpVs and stimulated with insulin. It was recently shown, that starved fibroblast need to be stimulated with a certain dose of growth factors in order to detect drug dependent changes in PKB phosphorylation (Byrne et al). Since PTEN inhibitors lead to the loss of PTEN activity and thus to increased PI(3,4,5)P3 levels, we expected a dose-dependent activation of PKB after treatment with vanadates. We clearly could demonstrate an increase of phosphorylated Ser473 in corelation with nanomolar bpV exposure of the cells (Figure 4a). Using densitometric analysis we established an inhibition of 50% between 48 and 99 nM for the different compounds. Those values are comparable to the results we received in our enzyme assays. The slight variation to the *in vitro* results might be due to retarded membrane permeability of the vanadates (No...). Since it is published that insulin and vanadate also activate PKB (No 184, 234), however, in higher concentrations than applied here, we repeated the same experiments in the PTEN negative UM-UC-3 cell line. As proposed, bpVs did not provoke PKB activation indicating that these compounds target PTEN (Figure 4b). Finally, to further confirm our findings we investigated the influence of the PI3K inhibitor Ly294002 in our cell system. If bpVs act via a PI3K-dependent pathway, one would expect that these compounds could rescue Ly294002 induced PKB inhibition. The application of an appropriate concentration of Ly294002 prevented PKB phosphorylation (Figure 5). However, co-treatment with bpV(pic) could abrogate this inhibition which clearly demonstrates that bpVs target PTEN which in turn leads to increased PI(3,4,5)P3 levels and to the activation of PI3K/PKB downstream pathways.

CLAIMS:

1. The use of a Vanadium containing compound of the formula:





- 5 wherein L-L' is :




and L' is COO, CONR⁵, CONHR⁶, CH₂NR⁵R⁶

10

or wherein L and L' together form a group:



- 15 or a group:



wherein L' is O, S or NH;

R¹, R², R³, R⁴, R⁵ and R⁶ are independently H, C₁₋₆ alkyl, optionally substituted by hydroxy or NR⁷R⁸, C₃₋₆ cycloalkyl, optionally substituted by hydroxy or NR⁷R⁸, phenyl, optionally substituted by C₁₋₃ alkyl, hydroxy, NR⁷R⁸ or SO₃, (OCH₂CH₂)_n


5 (NHCH₂CH₂)_n, an amino acid or a peptide consisting of 2 to 5 amino acids; and

R⁷ and R⁸ are independently H or C₁₋₆ alkyl;



or a pharmaceutically acceptable salt thereof

in the manufacture of a medicament for use in inhibiting phosphatases.

10 2. The use of a Vanadium containing compound of the formula:




15 wherein L-L' is :




and L' is COO, CONR⁵, CONHR⁶, CH₂NR⁵R⁶

20

or wherein L and L' together form a group:



or a group:



wherein L' is O, S or NH;

R¹, R², R³, R⁴, R⁵ and R⁶ are independently H, C₁₋₆ alkyl, optionally substituted by hydroxy or NR⁷R⁸, C₃₋₆ cycloalkyl, optionally substituted by hydroxy or NR⁷R⁸, phenyl, optionally substituted by C₁₋₃ alkyl, hydroxy, NR⁷R⁸ or SO₃, (OCH₂CH₂)_n, (NHCH₂CH₂)_n, an amino acid or a peptide consisting of 2 to 5 amino acids; and R⁷ and R⁸ are independently H or C₁₋₆ alkyl;

or a pharmaceutically acceptable salt thereof

in the manufacture of a medicament for use in inhibiting phosphatases.

3. The use as claimed in claim 1 or claim 2 wherein the medicament is for use in inhibiting inositol phosphatases such as PTEN.


4. The use as claimed in any one of claims 1 to 3 wherein the medicament is for use in treating diseases where inhibition of apoptosis is required.

5. The use as claimed in claim 4 wherein the disease or condition is a neurodegenerative disease such as Alzheimer's disease, wound healing, burns, heart hypertrophy, hypoxia, ischemia, sports injuries and as an anticancer agent.

6. The use as claimed in any one of claims 1 to 5 wherein the compound is potassium bisperoxo (bipyridine) oxovanadate (bpV(bipy)), potassium bisperoxo(1,10-



phenanthroline)oxovanadate (pV(phenanthroline)), potassium bisperoxo (piconline)oxovanadate (pV(pic)) and potassium bisperoxo(phenylbiguanide)oxovanadate (pV(biguan)).

5 7. A Vanadium containing compound of the formula:



where L-L' is :


10



and L' is CONR⁵ and CONHR⁶; and



wherein R¹ is C₁₋₆ alkyl.

15 8. A Vanadium containing compound of the formula:



where L-L' is :

20




and L' is $CONR^5$ and $CONHR^6$; and

wherein R^1 is C_{1-6} alkyl.


5

9. A Vanadium containing compound of the formula:



wherein L and L' together form a group:

10



wherein L'' is O, S or NH;

R^1 , R^2 , R^3 and R^4 are independently H, C_{1-6} alkyl, optionally substituted by hydroxy

15 or NR^7R^8 , C_{3-6} cycloalkyl, optionally substituted by hydroxy or NR^7R^8 , phenyl,

optionally substituted by C_{1-3} alkyl, hydroxy, NR^7R^8 or SO_3 , $(OCH_2CH_2)_n$

$(NHCH_2CH_2)_n$, an amino acid or a peptide consisting of 2 to 5 amino acids; and

R^7 and R^8 are independently H or C_{1-6} alkyl;

or a pharmaceutically acceptable salt thereof.

20

10. A pharmaceutical formulation comprising a compound as claimed in any one of claims 7 to 9, optionally together with one or more pharmaceutically acceptable excipients, diluents or carriers.

